Kornimate/medical-research-clean huggingface dataset:
dyslipidemia international survey-china

Conditions: the Prevalence,Lipid Abnormalities,

Summary: this cross-sectional, non-interventional, and observational study will assess the lipid profile of patients who have been taking lipid-modifying drugs (i.e., proportion of patients achieving treatment to goal according to national and international lipid management guidelines) during a single visit to their physicians on an outpatient basis in 6 representative geo-economic regions in china: northeast, north, east, south, southwest, and northwest; and within each region, in three tiers of hospitals: tier 3 (primary or teaching hospitals), tier 2 (secondary or city level hospitals), and tier 1 (community hospitals/health centers). the investigators will primarily be cardiologists, endocrinologists, neurologists, gerontologists, internists, or other physicians who are representative of the general population of physicians managing patients with dyslipidemia and/or at high risk for cardiovascular events likely to be treated with lipid-modifying drugs. demographic data, cardiovascular risk factors, a history of cardiovascular disease and cardiovascular treatments will be documented in a single visit through patient clinical examination and chart review. dysis-china is part of a string of epidemiological studies that share the same master protocol, which has been conducted in different countries mainly in europe and canada. the analysis of the pooled studies including overall data and cross-country comparisons is the subject of a distinct protocol.


Eligibility criteria:
inclusion criteria: 1. patient is an outpatient \> 45 years of age 2. patient is currently\* treated with a statin 3. patient has a documented fasting lipid profile (\> 1 lipid parameter within the last 12 months) performed while on lipid-modifying therapy for at least 3 months 4. patient agrees to participate in the study by giving informed consent. * patient is already being treated with a lipid-modifying drug just before the visit. patient for whom a lipid-modifying therapy is initiated at the time of the visit must not be included. exclusion criteria: 1. patient is currently participating in a clinical trial.

Keywords: the prevalence,lipid abnormalities,cv risks
intestinal microbiota transplant in alcohol-associated liver disease

Conditions: Liver Disease; Alcohol-Related; Cirrhosis; Alcohol Use Disorder

Summary: the purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.

these intestinal microbiota transplant (imt) capsules are an investigational drug, which means it has not been approved by the u. s. food and drug administration (fda). in this study, drug name will be compared to placebo (a look-alike inactive substance, a "sugar pill"). participants will be randomly assigned (like the flip of a coin) to receive either imt capsules or placebo capsules. participants have an equal chance of being assigned to any one of the groups. in this study, participants will be asked to do the following things: 1. visit vcu medical center up to 8 times for study visits 2. take either imt capsule or the placebo, depending upon which group they are assigned to; these capsules will be given twice on enrollment and after one month 3. have blood drawn, urine and stool collected at each visit 4. have testing done to determine the speed of brain function 5. keep a diary at home 6. take surveys and answer questions about general health, alcohol craving and consumption and how they are feeling. 7. give permission for the researchers to collect information about liver disease, alcohol and mental health from medical records. participation in this study will last up to 7 months.

Eligibility criteria:
inclusion criteria: -\>18 years of age * advanced liver disease * able to give written, informed consent * alcohol as a cause of advanced liver disease * continued sustained drinking * having previously declined a referral to traditional aud therapy services or having failed such treatments exclusion criteria: * lack of sustained drinking * recent or current alcoholic hepatitis * alcohol withdrawal symptoms * clinically significant use of illicit drugs * uncontrolled mood disorders or primary psychotic conditions * meld score\>17 * unclear diagnosis of chronic liver disease * current hepatic encephalopathy on lactulose and/or rifaximin * wbc count\<1000 * non-elective hospitalization within last month * on dialysis * known untreated, in-situ luminal gi cancers * chronic intrinsic gi diseases (ulcerative colitis, crohn's disease or microscopic colitis, eosinophilic gastroenteritis and celiac disease) * dysphagia within 2 weeks * history of aspiration, gastroparesis, intestinal obstruction * ongoing absorbable antibiotic use * severe anaphylactic food allergy * allergy to ingredients generally recognized as safe in the g3 capsules (glycerol, sodium chloride, hypromellose, gellan gum, titanium dioxide, theobroma oil) * adverse event attributable to prior imt * asa class iv or v * pregnant or nursing patients * acute illness or fever on the day of planned fmt * immunosuppression * other conditions which make patients are poor candidate for this study per investigator judgement

Keywords: intestinal microbiota transplant alcohol use disorder cirrhosis chronic liver disease
apostherapy for singaporean patients with knee osteoarthritis (oa)

Conditions: Knee Osteoarthritis

Summary: osteoarthritis (oa) is the most prevalent form of arthritis in the elderly. it is estimated that 7% of men and 11% of women over the age of 65 have koa. the most significant symptoms of the disease are pain and functional disability. this study has two aims: 1. to characterise the gait patterns and clinical parameters of patients with knee osteoarthritis (koa) in singapore at baseline, prior to treatment. 2. to investigate the changes in gait patterns and the clinical benefits of treatment with a new biomechanical device, apostherapy, for patients with koa.


Eligibility criteria:
inclusion criteria: * patients suffering from symptomatic bilateral knee osteoarthritis at the medial compartment for at least six months, fulfilling the acr clinical criteria for oa of the knee, and having radiographically assessed oa of the knee according to the kellgren and lawrence scale. * patients with an overall womac score of \>2cm (as measured at baseline). * males and females between the ages of 50-70. exclusion criteria: * patients suffering from acute septic arthritis. * patients suffering from inflammatory arthritis. * patients who received a corticosteroid injection within 3 months of the study. * patients suffering from avascular necrosis of the knee. * patients with a history of knee buckling or recent knee injury. * patients who have had a joint replacement. * patients suffering from neuropathic arthropathy. * patients with an increased tendency to fall. * patients exhibiting a lack of physical or mental ability to perform or comply with the study procedure. * patients with a history of pathological osteoporotic fracture. * patients suffering from symptomatic degenerative arthritis in lower limb joints other than the knees. * patients with referred pain in the knees from back or hip joint symptoms.
cancer distress coach mobile app trial

Conditions: Posttraumatic Stress Disorder; Cancer

Summary: the cancer distress coach (cdc) mobile app is a symptom management tool for posttraumatic stress disorder (ptsd) in cancer patients and caregivers. based largely on "ptsd coach" from the national center for ptsd, the cdc app was redesigned for both ios and android platforms and is tailored specifically to individuals impacted by cancer. this study aims to evaluate whether cdc app usage influences symptoms of ptsd through a randomized controlled trial (rct) where subjects are placed into either the intervention group or the wait-listed control group for a period of 8 weeks. the cdc app is available as a free download on the app store® and on google play™.


Eligibility criteria:
inclusion criteria: * have been diagnosed with cancer or are/were a caregiver to someone with cancer * resident of the united states of america * able to read and write english * age ≥ 18 years exclusion criteria: * none

Keywords: ptsd anxiety depression distress fear coping support caregiver oncology app mobile app
immunogenicity of a je-cv as a booster dose after a primary vaccination with sa14-14-2 vaccine

Conditions: Japanese Encephalitis

Summary: the objective of this study is to measured the geometric mean titer (gmt) of japanese encephalitis neutralizing antibody and proportion of seroprotection among the children who received a booster dose of je-cv after the first dose of sa14-14-2 vaccine.

study design: this open label clinical trial in 50 children aged 1-5 years, was conducted at king chulalongkorn memorial hospital in thailand. the protocol was approved by the institutional review board of chulalongkorn university, and the study was performed in accordance with declaration of helsinki, international conference on harmonization good clinical practice, the european directive 2001/20/ec, and written informed consent was obtained from parents or a legally acceptable representative before enrolment. vaccines: je-cv was manufactured by sanofi pasteur biologics co., usa., and reconstituted using 0.4% sodium chloride diluent for injection; each dose 0.5 ml contained 4.0-5.8 log10 plaque forming units of virus serology: je neutralizing antibody levels were assessed using a prnt50 assay. the final end point neutralization titer is the inverse of the highest serial dilution of serum that can neutralize ≥ 50% of je challenge virus. testing was performed at focus diagnostics inc. using je-cv as a challenge virus. statistical methods: sample size was calculated based on historical data from je15 study, at month 24 after first dose of je-cv, the gmt of je neutralizing antibody was 39.4 (95% ci 33.7 to 46.0) and increase to 2242 (95% ci 1913, 2628) at day 28 post je-cv booster dose. on the assumption that children who received sa14-14-2 vaccine and subsequently get one booster dose of je-cv at 12-24 months later will have gmt of at least 1040, with 80% power and alpha 0.05, data at least 43 children need to be collected. when accounted for 15% of children who might loss to follow-up or cannot get adequate blood sample, 50 children should be enrolled. the per-protocol population will be used for the main immunogenicity analyses. for the main parameters, 95% confidence intervals (cis) of point estimates will be calculated using the normal approximation for quantitative data and the exact binomial distribution for proportions. the point estimates and their 95% ci of the following will be presented for each group of the geometric mean (gm) of neutralizing antibody on d0 and d28 and the percentage of subjects with neutralizing antibody \>=10 at d0 and d28

Eligibility criteria:
inclusion criteria: 1 children aged 1 to \<5 years on the day of inclusion 2. history of received 1 dose of sa14-14-2 vaccine 12-24 months prior to enrollment 3. in good general health at the time of inclusion 4. provision of informed consent by the parent(s) or legal guardian(s) exclusion criteria: 1. receipt of blood or blood products in the past 3 months. 2. acute febrile illness on the day of vaccination.( bt \> 38 c)

Keywords: geometric mean titer seroprotection live attenuated chimeric je vaccine je-cv sa14-14-2 vaccine
steroid-sparing effect with pimecrolimus in pediatric patients with atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this study will investigate the steroid sparing effect of pimecrolimus cream 1% in pediatric atopic dermatitis


Eligibility criteria:
inclusion criteria: * outpatients aged 2 to \< 18 years with severe ad (score 8 or 9 according to rajka and langeland) * responded to 21 days of treatment with prednicarbate cream 0.25% during screening phase exclusion criteria: * patients who had received phototherapy, systemic or topical therapy or systemic corticosteroids shortly prior to study

Keywords: pimecrolimus, atopic dermatitis, eczema, pediatric
sub-therapeutic gnrh- antagonist treatment to rectify lh pulsatility in lean women with pcos.

Conditions: Polycystic Ovary Syndrome

Summary: the clinical study using a sub-therapeutic dose of a gnrh antagonist to reduce overactive lh pulsatility in women with pcos. with the intervention and lowered lh action we anticipate to decrease androgen levels in women with pcos. the aim to show for the first time that low-dose gnrh-antagonists can lower lh pulsatility by 20-30% and decrease androgen levels without blunting the hypothalamic-pituitary-gonadal axis and thereby the reproductive functions.


Eligibility criteria:
inclusion criteria: * minimum weight of 51 kg * bmi between 20 and 25 * women with pcos with amh\> 28 pmol / l, lh\> 8 iu / ml and testosteronemia \> 0.39 ng/ml * no hormonal treatment or contraception for 2 months * women covered by the social security system exclusion criteria: * hormonal treatment or hormonal contraception * metformin treatment * pregnant woman * inability to understand the newsletter

Keywords: pcos gnrh antagonist lh androgen testosterone
long-term endoscopic follow-up of benign epithelial gastric polyps

Conditions: Benign Gastric Polyp

Summary: benign epithelial gastric polyps are benign raised lesions that originate from the gastric mucosa or submucosa and protrude from the gastric cavity with a wide base or a pedicle.the diagnosis and treatment of benign epithelial gastric polyps are currently controversial. there is still a lack of clinical research evidence especially for the malignant tendency and related treatments of gastric polyps. many doctors have ambiguous understanding of benign epithelial gastric polyps and their endoscopic management is still in a"one size fits all"mode in china, which greatly wastes medical resources and increases the medical risks of patients, so it is imminent to formulate management practices for the diagnosis and treatment of gastric polyps. therefore, a full understanding of the clinical characteristics, endoscopic characteristics and long-term follow-up trends of benign epithelial gastric polyps is of great significance for clinicians to formulate reasonable treatment and follow-up plans. this study is a prospective, large-sample observational cohort study. it is planned to include 200 patients with biopsy confirmed benign epithelial gastric polyps participating in this study from september 10, 2020 to december 31, 2021 and followed up for 18 months. the main research endpoint is the correlation between size and pathological type of benign epithelial gastric polyps and polyps development. the secondary research endpoint is the correlation between type of benign epithelial gastric polyps and helicobacter pylori infection. the research results will help provide long-term follow-up data for benign epithelial gastric polyps of different pathological types, thereby providing first-hand evidence-based medical data for formulating gastric polyp management guidelines, helping to efficiently screen high-risk groups and guiding their examination, treatment and long-term follow-up to achieve early detection and early treatment of gastric cancer, thereby reducing the mortality rate.


Eligibility criteria:
inclusion criteria: * after gastroscopy, gastric polyps are found and pathological biopsy is obtained. all polyps undergo endoscopic clamp biopsy, requiring at least one piece of tissue from each polyp to be submitted for examination. exclusion criteria: * submucosal raised lesions. * gastrointestinal bleeding. * concomitant with gastric malignant tumor disease or previous gastric surgery for any reason. * benign polyps with a diameter greater than 1cm, regardless of the pathological type. * the patient also has other serious diseases that affect the evaluation of this study, such as severe liver disease, heart disease, kidney disease, malignant tumors and alcoholism. * the patient cannot express his main complaint correctly, such as mental illness, severe neurosis, and cannot cooperate with the trial.

Keywords: benign gastric polyp gastroendoscopy pathological type
classification of breast masses based on visco-elastic properties using save method

Conditions: Breast Cancer

Summary: the purpose of this research is to conduct a clinical study to evaluate the efficacy of a noninvasive and quantitative tool for classification/diagnosis of breast masses. the main objective of this proposal is to test the save (sub-hertz analysis of visco-elasticity) method on a patient population of sufficient size to determine the sensitivity and specificity for malignant-benign discrimination of breast masses.

subject will sit or lie back on an examination bed. the investigators will use an ultrasound scanner to collect sonographic imaging data from the breast. for this purpose the investigators may use a clinical scanner such as supersonics aixplorer or similar or a research ultrasound machine such as verasonics (this machine has been use in other mayo irb approved protocols such as irb 11-001953). the ultrasound probe will be placed on the breast to visualize the mass. the probe will be pressed with a constant force for a period of 10-40 seconds. during this time ultrasound data will be recorded by the ultrasound scanner. to keep the probe pressed on the breast with a constant force, the user may hold the probe by hand and press it steadily against the breast at constant force. this force is only a few newtons (approximately half a kg weight) which should be quite tolerable for a typical patient. alternatively, the investigators may use an automated "actuator" to hold the probe steady and press it against the breast at a constant force to the same level. the reason for pressing the breast is to determine how the breast tissue gradually deforms; therefore this method to some extent simulates breast palpation. the time needed to scan a subject for this study is short (a few minutes to set up, and about 10-40 seconds to scan). it will take approximately 20 minutes to complete the study. the scan can be done at the time of clinical breast sonography. the subject may be asked to hold her breath during the scan time if possible. the investigators call this method "sub-hertz analysis of visco-elasticity (save)". to facilitate subject access and shorten patient participation time, the investigator may station our system in the breast imaging area where routine clinical imaging procedures are performed. the investigators may also use the fda approved ge logiq e9 (le9) ultrasound system to quantify and image the stiffness of the breast lesion and compare the results to those obtained by the investigational device. the investigators may also use the alpinion clinical ultrasound machine, both fda approved clinical format ecube 12 and non fda approved ecube 12r format to acquire ultrasound images.

Eligibility criteria:
inclusion criteria: * females in age range between 18 and up who have a breast lesion that may or may not be suspicious for breast cancer, and are referred for radiological investigation. exclusion criteria: * no history of mastectomy or implants, or having any condition that does not allow proper use of our imaging devices. * only include patients with masses detectable under ultrasound.
awareness of gynaecologists about role of physical therapy in genital prolapse

Conditions: Genital Prolapse

Summary: the aim of this study will be to detect if there is awareness of gynecologists about the role of physical therapy in genital prolapse. physical therapy plays an important role in assessment, prevention and treatment of pelvic floor dysfunction and genital prolapse, it helps to stimulate and strength pelvic floor muscle. physical therapy treatments for the pelvic floor may include bladder training, pelvic floor muscles training with or without biofeedback, vaginal cones, electro stimulation or other adjuncts to training.


Eligibility criteria:
inclusion criteria: - gynaecologists in private and government hospitals in egypt exclusion criteria: * gynaecologists with less than 5years experience.
effects of bariatric surgery in swedish obese subjects

Conditions: Obesity

Summary: the purpose of the swedish obese subjects (sos) study is to examine the long-term effects of bariatric surgery on overall mortality and obesity-related co-morbidities.

the swedish obese subjects (sos) study is a prospective non-randomized controlled intervention study designed to examine the long-term effects of bariatric surgery compared to usual care in obese subjects.

Eligibility criteria:
inclusion criteria: * age 37-60 years and bmi ≥34 kg/m2 in men and ≥38 kg/m2 in women. exclusion criteria: * exclusion criteria of both groups were: earlier operation for gastric or duodenal ulcer; earlier bariatric surgery * gastric ulcer during the past 6 months; ongoing malignancy * active malignancy during the past 5 years * myocardial infarction during the past 6 months * bulimic eating pattern; drug or alcohol (\>0·75 l 40% liquor per week or corresponding amount of ethanol) abuse * psychiatric or cooperative problems contraindicating bariatric surgery * other contraindicating conditions (such as continuous glucocorticoid or anti-inflammatory treatment).

Keywords: obesity bariatric surgery weight loss